Author

admin

Browsing

Investor Insight

An innovative technology that promises positive economics place Altech Batteries in a compelling position to take advantage of a booming batteries market driven by global electrification and clean energy transition.

Overview

Altech Batteries (ASX:ATC,FRA:A3Y) is a battery technology company focused on commercialising the revolutionary CERENERGY® Sodium-Chloride Solid State (SCSS) Battery, destined for the renewable energy grid storage market. The SCSS Battery does not require lithium, cobalt, copper, graphite or manganese, bypassing these high-demand and expensive minerals, and leverages a novel sodium-chloride (common table salt) technology to produce a more durable and longer-lasting battery. This new battery uses cheaper and readily available sodium rather than the more scarce, costly, and risky lithium. Lastly, Altech is headed by an experienced team who understands what it takes to bring transformative technology to market.

That’s not all Altech has going for it, either. Unlike other energy storage options, the Company’s new SCSS Battery technology promises to solve many issues associated with traditional lithium batteries, including fire and explosion risks, manufacturing costs, operating temperature ranges and lifespans.

The reality is simple: Lithium-ion batteries have been susceptible to fire and explosions and have even malfunctioned in certain temperatures — all critical issues that must be solved to ensure long-term sustainability.

CERENERGY® batteries solve these challenges. For example, they do not contain any volatile flammable electrolyte or plastic separator and use a solid-state ceramic tube. Simply put, the thermal runaway problem that’s plaguing lithium-ion batteries is not possible with Altech’s new battery technology.

Altech has a joint venture agreement with the German government battery institute Fraunhofer IKTS, which has been developing the CERENERGY® battery over the past eight years and invested over €35 million in research and development. Now, Altech is commercialising the technology by providing expertise and resources to build a new 120-MWh-per-annum plantin Saxony, Germany, on Altech’s land.

In 2024, the pilot line at Fraunhofer IKTS in Hermsdorf, Germany underwent a comprehensive redesign to facilitate the manufacturing of two ABS60 60 kWh battery prototypes. Innovative tools and machinery have been developed and implemented specifically for producing the battery cells required for the 60 kWh prototypes. The battery pack is composed of 240 CERENERGY® cells, each rated at 2.5 volts with dimensional specifications of 2.6 meters in height, 0.4 meters in length, and 1 meter in width.

Altech Batteries also released the results from a Definitive Feasibility Study (DFS) conducted for the CERENERGY® project with an annual capacity of 120 MWh GridPacks. DFS showed a capital cost estimated at €156 million (US$170.15 million) with excellent project economics.

The CERENERGY® project is being developed by Altech Batteries GmbH (ABG) with 75 percent interest and joint venture partner Fraunhofer IKTS with 25 percent interest. ABG is 75 percent owned by Altech Batteries and Altech Advanced Materials AG (FSE:AMA).

Altech is moving forward to obtain sales offtake for the project and sourcing funding to construct the plant.

Company Highlights

Altech Batteries is a battery technology company commercialising its revolutionary CERENERGY® Sodium-Chloride Solid State (SCSS) Battery that uses common table salt technology.Altech’s proprietary technology does not require lithium, cobalt, copper or graphite, eliminating cost, ethical, safety and supply chain issues.Compared to lithium-ion batteries, the CERENERGY® battery is fire and explosion-proof, is cheaper to manufacture, suitable in any temperature range and provides a greater lifespan.Altech has a joint venture agreement with Fraunhofer IKTS, the German Government’s Battery Institute that has been developing the SCSS technology for eight years with significant financial investment.The joint venture is building a new 120 MWh plant in Saxony, Germany to manufacture the new SCSS 1 MWh GridPack, designed for the lucrative and growing grid storage market.Additionally, Altech is building a pilot plant for its Silumina AnodesTM product, designed to improve lithium-ion batteries by providing a higher capacity anode for the EV market. This patented technology involves coating silicon and graphite with high-purity alumina, increasing the capacity of lithium-ion batteries by 30 percent compared to traditional graphite only anodes.Through a Definitive Feasibility Study, Altech expanded the Silumina AnodesTM project output by eightfold, increasing the capacity from 15 gigawatt-hours (GWh) to 120 GWh.

Key Projects

CERENERGY® Sodium-Chloride Solid State Battery Project

Altech Batteries and Fraunhofer IKTS are currently commercialising the Sodium-Chloride Solid State (SCSS) battery technology, which uses sodium over lithium. It is a solution geared toward the renewable energy grid storage market, an often overlooked but significant market for the transition to renewable energy.

Project Highlights:

Solves Major Issues with Lithium-Ion Batteries: We’ve seen challenges with lithium-ion batteries become news stories as these batteries experience thermal runaway or cannot operate outside an ideal temperature range. CERENERGY® battery technology does not use combustible liquid electrolytes and has a significantly improved temperature range of -40 to 60 degrees Celsius.Impressive Shelf Life and Operating Life: Unlike lithium-ion batteries, the CERENERGY® battery does not use a liquid electrolyte, meaning it does not deteriorate over time; there is no loss of sodium. CERENERGY® batteries have extended shelf life compared to lithium-ion and an operating lifespan of over 15 years, which also exceeds lithium batteries.Pilot Plant and New GridPack Underway: Altech Batteries and Fraunhofer IKTS are now commercialising the technology with a new 100 MWh plant in Saxony. Additionally, Altech recently announced its new 1 MWh GridPack designed for grid storage. The new GridPack is suitable for all weather conditions, has low maintenance costs, and has a long battery life.

Silumina Anodes Pilot Plant

Altech Batteries has purchased the land in Saxony, Germany, for its 8,000-tpa proprietary Silumina AnodesTM battery materials plant. The plant has a completed pre-feasibility study with outstanding economics. The company strategically selected the plant’s location to serve the European battery market. The pilot plant will be built adjacent to the land.

Project Highlights:

Plant Designed for Minimal Environmental Impact: The Centre of International Climate and Environmental Research (CICERO), located in Norway, has reviewed the plant’s design and awarded it the rating of “Medium Green.” This rating indicates that the project achieves ‘green’ financing.Feedstock Supply of Battery-Grade Anode Materials Secured: Altech Batteries has executed a Memorandum of Understanding (MoU) with two European suppliers of battery-grade materials: SGL Carbon and Ferroglobe.

Management Team

Luke Frederick Atkins – Non-executive Chairman

Luke Frederick Atkins is a lawyer by profession and one of the founders of the company. Atkins brings to the board extensive experience in the areas of mining, exploration and corporate governance. Atkins is also non-executive director of the successful ASX-listed mining and exploration company, Bauxite Resources (BRL) (now Australian Silica Quartz). Atkins formerly held the role of executive chairman of BRL after co-founding the company in 2007. He has played a key role in BRL third party negotiations to successfully access funding, joint venture partnerships, land and infrastructure. Atkins has had extensive experience in capital raising and has held some executive and non-executive directorships of private and publicly listed companies including several mining and exploration companies.

Iggy Tan – Managing Director

Iggy Tan is a highly experienced mining and chemical executive with several significant achievements in commercial mining projects such as capital raising, funding, construction, start-ups and operations. Tan has over 30 years of chemical and mining experience and has been an executive director of some ASX-listed companies. He holds a Master of Business Administration from the University of Southern Cross, a Bachelor of Science from the University of Western Australia, and a graduate of the Australian Institute of Company Directors.

Tan is responsible for managing and implementing the next stage of Altech’s strategic business objectives. Having been involved in the commissioning and start-up of seven resource projects in Australia and overseas, including high-purity technology projects, Tan is an accomplished project builder and developer.

He was the managing director of Nickelore, Galaxy Resources and Kogi Iron. At Galaxy, Tan was responsible for capital raising, construction and start-up of the company’s Mt Cattlin spodumene mine ($80 million) and the Jiangsu lithium carbonate plant ($100 million), which resulted in Galaxy becoming the world’s leading producer of high-purity lithium carbonate. The Jiangsu plant was eventually sold for $260 million in 2014.

Uwe Ahrens – Alternate Director

Uwe Ahrens is the executive director of Melewar Industrial Group Berhad and managing director of Melewar Integrated Engineering Sdn Bhd. He is also on the board of other private limited companies. Ahrens holds masters in both mechanical engineering and business administration from the Technical University Darmstadt, Germany. Upon graduation, Ahrens joined the international engineering and industrial plant supplier, KOCH Transporttechnik GmbH in Germany, now part of FLSmidth Group, where he held a senior management position for 12 years, working mainly in Germany, the USA and South Africa.

In 1997, Ahrens was the general manager of KOCH in South East Asia and became its managing director in 1999. He joined Melewar Group in 2002 and is also currently chief technical officer of the Melewar group of companies responsible for engineering, upgrading, modification and extension of machinery and plant, as well as the overall maintenance.

Martin Stein – Chief Financial Officer & Company Secretary

Martin Stein is a finance and corporate executive with over 20 years of international experience. Stein has been the chief financial officer and company secretary for several ASX-listed companies. In these roles, he was responsible for all aspects of capital raising, financial management, shareholder liaison and corporate governance.

Before this, Stein held senior positions with Anvil Mining as well as with PwC at its London office. Whilst with PwC, he provided corporate services for companies listed on the LSE, NYSE and AIM, including Colgate-Palmolive, Sony, Heinz, DHL Express and Bosch.

This post appeared first on investingnews.com

The US Federal Reserve reduced its benchmark interest rate for the first time in four years on Wednesday (September 18), beginning its cutting cycle with a sizeable 50 basis point reduction.

The Federal Open Market Committee has held rates steady since July 2023 after starting to hike in March 2022.

Speaking at a press conference after the decision, Fed Chair Jerome Powell said the US economy has come into balance, which means the time has come to cut rates. He added that the cut puts the central bank in a good position to respond quickly with changes should inflation begin to reverse or should the labor market deteriorate.

When asked if the Fed made a larger cut because it’s trying to catch up, Powell said the central bank hasn’t fallen behind — instead it’s taking strong measures to avoid falling behind. He suggested that the committee has been patient in making its policy decisions and said he believes that keeping rates higher for longer has benefited the US economy.

Powell added that while the upside risk to inflation has decreased, the downside risk to employment markets has increased. He also indicated that he is encouraged by inflation coming closer to the Fed’s 2 percent target, but said more data will be needed to demonstrate inflation is sustainably within the target range before declaring victory.

The 12 Federal Open Market Committee members were not unanimous in their decision, with Fed Governor Michelle Bowman casting the sole dissenting vote, indicating that she would have preferred a 25 point reduction.

It marks the first time since 2005 that a governor has voted against a policy change. Powell said there was good discussion at the meeting, suggesting that despite the difference of opinion there was also much common ground.

Dr. Stephen R. Foerster, professor of finance at the Ivey School of Business, said a 50 point cut will provide a more stimulative effect on the American economy, but highlighted the impact won’t be known immediately.

Ultimately, the cut could be a boon for commodities investors. “Rate cuts often make commodities more attractive on a relative basis. Lower rates lower the cost of carrying inventories which should increase commodity prices,” Foerster said.

In the longer term, Saidel-Baker sees up to 100 points of total cuts between now and the first half of 2025, a viewpoint that’s at odds with the broader market expectation of 200 points.

Markets saw increased volatility following the Fed’s announcement. The S&P 500 (INDEXSP:INX) was down by 0.29 percent to 5,618.25 points, while the Nasdaq-100 (INDEXNASDAQ:NDX) fell 0.45 percent to 19,344.49 points and the Dow Jones Industrial Average (INDEXDJX:.DJI) closed just 0.25 percent lower to 41,503.11 points.

Precious metals were volatile, with gold peaking during afternoon trading at US$2,599 per ounce; it ultimately retracted and at 4:00 p.m. EDT was down 0.48 percent to US$2,557.16. Likewise, silver saw a sharp gain following the announcement to trade above the US$31 per ounce mark, but ultimately shed 2.04 percent to US$30.05.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

GTI Energy Limited (ASX: GTR) (GTI or Company) advises that the 73 resource development drill holes planned for 2024 have now been completed at its 100% owned Lo Herma ISR Uranium Project (Lo Herma), located in Wyoming’s Powder River Basin. GTI has completed 16,205m (53,166 ft) of drilling at Lo Herma this summer representing ~96% of the planned 76-hole program. The remaining hydrogeologic focused drill holes and water monitoring wells will be completed during October.

HIGHLIGHTS

7 additional drill holes completed at the Lo Herma ISR uranium project with all 73 resource development holes planned for 2024 now completedDrilling confirms deeper uranium mineralisation at elevated grades within the upper Fort Union Formation, presenting significant upside potential for Lo HermaBest mineralised intercepts reported include 3.5ft (1m) at 0.185% (1,850ppm) eU308 in hole LH-24-071, and 6.5ft (2m) at 0.074% (740ppm) eU308 in hole LH-24-069Best total hole GT of 1.092 over 23.5 ft (7.16m) in 5 stacked sand units in LH-24-069

This release follows on from GTI’s 31 July 2024 and 11 September 2024 news releases which together reported results from the first sixty-six (66) drill holes. Results from this next seven (7) drill holes (Table 1) included six (6) holes which purposely targeted deeper mineralisation in the upper Fort Union Formation (Figure 2) and delivered the following highlights:

Drill hole LH-24-071 returned the highest-grade intercept at 3.5ft (1m) of 0.185% eU3O8, and a total hole grade thickness (GT) of 0.800*.Significant mineralisation is present in multiple sands units within the upper Fort Union Formation, as demonstrated by hole LH-24-069 which encountered 6.5 ft (2m) of 0.074% eU3O8, 7.5ft (2.3m) of 0.030% eU3O8, and 6.5ft (2m) of 0.046% eU3O8 for a total hole GT of 1.092 across 23.5 ft (7.16m) in 5 stacked sand units.5 of 6 holes targeting the Fort Union Formation intercepted on trend mineralisation, with 4 holes exceeding minimum GT resource cutoff and one hole lost before it could be logged.
* Typical economically viable ISR grade and GT cut-offs are: 0.02% (200ppm) U3O8 and 0.2GT i.e., 10 ft (3 m) @ .02% (200ppm) U3O8.

GTI Director & CEO Bruce Lane commented“We are delighted that these results confirm excellent grades across good thicknesses in multiple stacked sands of the Fort Union formation. We remain very optimistic that additional pounds from this eastern part of Lo Herma can be bought into resource. This year’s drilling has successfully confirmed that stacked sand units of both the lower Wasatch & upper Fort Union contain reliable continuity of mineralisation across extended areas of the project. The 2024 resource drilling is now completed with hydrogeologic and water monitoring wells to be completed in October. Following completion of that work, we plan to update the Mineral Resource Estimate and Exploration Target for Lo Herma by year end.”

DRILLING RESULTS

Mud rotary drilling commenced at Lo Herma on Wednesday, 24 July 2024. Over the first three days of drilling, ten (10) drill holes were completed for a total of 1,908m (6,260 ft) of drilling. Results of those drill holes were previously announced to the ASX on 30 July 2024. Subsequent to that, GTI reported the results of drill holes 11 through 66 on 11 September 2024. The results of the next seven (7) drill holes, 6 of which targeted mineralisation in the deeper Fort Union formation (Figure 2), are reported here.

The current drill program was designed to further expand the mineral resource, upgrade the classification of a portion of the inferred mineral resource, and collect additional geochemical and hydrogeologic data necessary to advance a scoping study for Lo Herma.

Of the seven (7) drill holes reported here, six (6) drill holes targeted deeper mineralisation in the Fort Union Formation. Of those drill holes, four (4) drill holes exceeded the minimum grade cutoff of 200 ppm eU3O8 and the total hole grade-thickness (GT) cutoff of 0.2 GT, one (1) drill hole demonstrated trace mineralisation but did not meet the grade cutoff, and one drill hole was lost before the downhole gamma log could be completed. An additional drill hole in the northern extent of the property reported here encountered trace mineralisation.

All drill holes completed were beneficial in determining the lateral geometry of the sinuous roll front type uranium deposits present at Lo Herma across multiple sandstone units.

The best individual mineralised intercept was encountered in drill hole LH-24-071 which encountered 3.5ft (1m) of 0.185% (1,850 ppm) eU3O8 from a depth of 1302.5 ft, providing a 0.648 GT for the intercept. The total hole GT for drill hole LH-24-071 was 0.800. The greatest total Hole GT was encountered in drill hole LH-24-069, which encountered mineralisation above the 0.02% eU3O8 cut-off within five (5) sand units, providing a total hole GT of 1.092.

Click here for the full ASX Release

This post appeared first on investingnews.com

Sarama Resources Ltd. (“Sarama” or the “Company”) (ASX:SRR, TSX- V:SWA) is pleased to report that on 18 September 2024, it had completed the issue of shares in part settlement of deferred executive salaries and director fees (the “Compensation Shares” or the “Shares for Debt”) as previously announced in a news release dated 17 July 2024.

The Shares for Debt arrangement comprised the issue of 22,348,980 Chess Depository Instruments (“CDIs”) at a deemed issue price of A$0.02 per CDI, equivalent to A$446,979.60 as detailed in Table 1 below. Each new CDI issued under the Placement will rank equally with existing CDIs on issue and each CDI will represent a beneficial interest in one common share of the Company. The issuance of the Shares for Debt was subject to TSXV and shareholder approval which was obtained at the annual general meeting held on 11 September 2024 (the “Meeting”).

The Compensation Shares and Shares for Debt were issued upon receipt of shareholder approval, as required by the Australian Securities Exchange Listing Rules, at the Meeting. An Appendix 2A was announced to the ASX on 18 September 2024 and provides further detail on the issue of the Compensation Shares and Shares for Debt.

The Share for Debt arrangement will reduce the Company’s liabilities.

The CDIs issued under the Placement are subject to a TSX Venture Exchange (“TSXV”) “hold period” of 4 months and one day from the date of issue of the CDIs.

The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from registration is available. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of the Securities within the United States or to, or for the account or benefit of, U.S. Persons (as defined under Regulation S under the U.S. Securities Act), nor shall there be any sale of these Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Click here for the full ASX Release

This post appeared first on investingnews.com

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

1. Eli Lilly and Company (NYSE:LLY)

Company Profile

Market cap: US$860.11 billion

Founded in 1876, Eli Lilly and Company employs approximately 10,000 individuals for research and development in seven countries and has products marketed in 110 countries, including therapies for diabetes, cancer, immune system diseases and a wide range of mental health conditions. The company also has drugs in development for various medical conditions, such as skin ailments, cancers, Crohn’s disease, diabetes, obesity and Alzheimer’s disease.

Eli Lilly’s Alzheimer’s disease drug donanemab completed its Phase 3 trial in May 2023, with test results showing ‘significant’ slowing of cognitive and functional decline for people with early symptoms of the disease. The drug, sold under the name Kisunla, was approved by the US Food and Drug Administration on July 2, 2024.

2. Novo Nordisk (NYSE:NVO)

Company Profile

Market cap: US$594.89 billion

Danish company Novo Nordisk has demonstrated a commitment to addressing various health conditions, such as type I and II diabetes, obesity, hemophilia and growth disorders, and markets its therapies in 170 countries. The company’s main product is the diabetes drug Ozempic, which is also marketed for obesity under the name Wegovy

It has been conducting research into a new obesity treatment called amycretin, which targets both GLP-1 and amylin receptors. Phase 2 trials are ongoing, but early-stage results show that volunteers taking amycretin have lost up to 13.1 percent of their body weight after 12 weeks, compared to 6 percent seen in patients taking Wegovy, which only targets GLP-1, according to the company.

Novo Nordisk has a working partnership with Microsoft (NYSE:MSFT) through which it uses the tech giant’s artificial intelligence (AI), cloud and computational services to facilitate the discovery of new drugs and treatments. The firm announced in March it will work with AI heavyweight NVIDIA (NASDAQ:NVDA) to build the Danish Center for AI Innovation, which will host an NVIDIA supercomputer and will run on 100 percent renewable energy.

3. Johnson & Johnson (NYSE:JNJ)

Company Profile

Market cap: US$399.96 billion

Johnson & Johnson operates on a massive scale and encompasses various segments through its subsidiaries. Its primary pharmaceutical subsidiary is Janssen Pharmaceuticals, which focuses on cardiovascular disease and metabolism, infectious diseases and vaccines, neuroscience, oncology, immunology and pulmonary hypertension.

Johnson & Johnson acquired a clinical-stage biopharmaceutical company called Ambrx Biopharma on July 3, which will allow the company to further develop antibody-drug conjugates, expanding its offering of targeted oncology therapies.

On January 30, following positive data from a Phase III study, the company submitted its drug Darzalex Faspro to the FDA for the treatment of newly diagnosed multiple myeloma in patients who are eligible to receive a transplant. The agency approved the treatment on July 30. The same request was submitted to the European Medicines Agency on March 4, but it has not received approval there at the time of this writing.

4. Merck & Company (NYSE:MRK)

Company Profile

Market cap: US$300.73 billion

Merck & Company has an extensive portfolio of products, including treatments for conditions such as diabetes and cancer, as well as vaccines for a variety of diseases.

Merck has a robust research and development pipeline, with over 80 programs currently in Phase II trials, over 30 in Phase III trials and more than 10 under review. The company is actively pursuing treatments for a range of conditions, including HIV, Ebola, hepatitis C, cardio-metabolic disease and antibiotic-resistant infections.

On March 13, Merck revealed plans to develop a new version of its human papillomavirus (HPV) vaccine Gardasil; it will be a multi-valent vaccine that will protect against more strains of HPV. The company also plans to run a separate trial to evaluate the results of a single dose of Gardasil 9, its current vaccine, compared to the previous three-dose regimen. Merck intends to begin the two trials in the fourth quarter of 2024.

On September 18, the FDA approved Merck’s cancer drug Keytruda for the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in adult patients, in combination with pemetrexed and platinum chemotherapy.

5. AbbVie (NYSE:ABBV)

Company Profile

Market cap: US$340.8 billion

AbbVie is a global biopharmaceutical company that discovers and delivers innovative medicines and solutions to address complex health issues. The company has identified five areas of focus where it believes it can make a significant impact in improving treatments for patients: immunology, oncology, neuroscience, eye care and aesthetics.

Its biggest performer was Humira, a therapy for autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, but its exclusivity ended in 2023 and biosimilars have now entered the market.

On February 28, AbbVie announced a strategic partnership with OSE Immunotherapeutics (LSE:0RAD,EPA:OSE), a clinical-stage immunotherapy company, to develop a monoclonal antibody to treat chronic and severe inflammation.

‘This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally,’ said Jonathon Sedgwick, PhD, senior vice president and global head of discovery research at AbbVie.

The firm cemented that point with the March 25 news that it has entered a definitive agreement to acquire Landos Biopharma (NASDAQ:LABP), a clinical-stage biopharma company that develops oral therapeutics for autoimmune diseases.

AbbVie declared a quarterly dividend of US$1.55 per share on September 6, payable on November 15, 2024.

FAQs for pharmaceutical stocks

What does the pharmaceutical industry do?

The pharmaceutical industry encompasses a variety of companies that have different — although sometimes overlapping — roles to play. The most famous players are the ‘Big Pharma’ companies. These giants often have a variety of subsidiaries, large pipelines and many products in their portfolios.

There are also smaller pharma R&D companies, which sometimes get acquired by larger firms if their work seems promising. Companies in these categories research, develop and bring to market drugs aimed at filling unmet needs, or helping people who are resistant to pre-existing treatments.

Once patents run out on prescription drugs, generic drug manufacturers create much cheaper generic versions. Wholesale companies also play a large role in the pharma sector. According to Common Wealth Fund, wholesalers have four areas through which they affect drug buying and distribution: ‘setting generic drug prices, leveraging list price increases, competing in specialty drug distribution, and mitigating or exacerbating drug shortages.’

What is the big pharma business model?

Big Pharma companies have a fairly consistent business model. Often, the company’s R&D team will slowly develop a new drug through many stages of testing to prove the drug’s efficacy, safety and necessity.

If all trials are completed successfully, the company will apply to government organizations such as the FDA, which must approve the drug before it can be mass produced, marketed and sold. Companies can skip a number of these steps by acquiring smaller companies, or through in-licensing, which results in two companies sharing the burden of a drug’s development through to commercialization. However, it’s worth noting that large pharma companies have many drugs in their pipelines at any given time, and many don’t make it to approval.

Once a drug is approved by the relevant health organization, it can be marketed and prescribed. Because patents expire after 20 years, companies lobby and advertise to try to get as many sales as possible during that window.

Who are the ‘Big 3’ in pharma?

The ‘Big 3’ in pharma refers to the three largest wholesalers: AmerisourceBergen (NYSE:ABC), Cardinal Health (NYSE:CAH) and McKesson (NYSE:MCK). Collectively, those three companies account for over 92 percent of wholesale prescription drug distribution in the US.

Which country is number one in the pharma industry?

The US is the top pharmaceutical country, with five of the top 10 pharma companies by revenue headquartered in the nation. The country is also in the lead when it comes to consumer spending on pharmaceuticals — this is due to the high cost of brand-name drugs. Aside from that, the US is the top country globally for R&D spending — companies that are part of PhRMA, a trade group that represents US biopharmaceutical companies, spent US$100.84 billion on R&D in 2022 out of a total of US$244 billion spent by pharmaceutical companies globally that year.

What are the problems in the pharmaceutical industry?

One of the largest problems with the pharmaceutical industry, particularly in the US, is the high cost of treatments. According to a study looking at American prescription drug spending between 2016 and 2021, prescription drug prices were 2.5 times the cost on average of prices in similar high-income nations.

In early 2023, US President Joe Biden signed the Inflation Reduction Act (IRA) into law intending to reduce healthcare costs and improve access to medications for patients; however, it may present new challenges and opportunities for pharmaceutical companies as they adapt to the evolving regulatory and market landscape.

Critics have argued that the IRA could negatively impact drug development and innovation due to additional regulatory hurdles and increased operational costs, potentially reducing the incentive to invest in R&D. Additionally, the IRA requires drug companies to pay rebates to Medicare if they raise the price of drugs faster than inflation. If the industry can’t adjust its prices in response to market conditions, it could deter investment in new drug development.

What is the future of pharmaceuticals?

Pharmaceutical companies will have to adapt to changing times. The world is shifting, with economic woes, geopolitical disruptions and supply chain concerns affecting nearly every sector. Innovation continues to accelerate as well, and the medical landscape has changed in the wake of COVID-19. Additionally, the US government is making moves to address the astronomical prices of prescription medicine as the industry comes under more scrutiny.

For a look at what is else is effecting the market, read our 2024 Pharma Market Forecast.

Are pharmaceutical stocks risky?

While established players like the Big Pharma and wholesale companies discussed above should be relatively consistent, small companies are make-or-break depending on whether their drugs are successful. This means that investors could see much higher returns compared to large companies, but run the risk of taking massive losses in the case of failure.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

NioCorp Developments (NASDAQ:NB) said on Wednesday (September 18) that it will discuss its plans for producing and potentially recycling rare earth elements at the International Rare Earths Conference.

The event will be held in Washington, DC, and NioCorp will present on October 15. The company will focus on its efforts to produce magnetic rare earth oxides, such as dysprosium and terbium, at its Elk Creek project.

In addition to production, the company will explore the possibility of recycling post-consumer rare earth magnets, aiming to contribute to a growing need for sustainable rare earths supply chains.

Elk Creek, which is located in Nebraska, is designed to utilize a whole ore leach process that would allow NioCorp to extract niobium, scandium, titanium and potentially rare earth oxides from the site.

According to the company, the asset contains the largest indicated terbium resource in the US, as well as the second largest indicated neodymium-praseodymium and dysprosium resources.

The project’s scope may include the recycling of neodymium-iron-boron (NdFeB) magnets, which are commonly used in various high-tech applications, such as electric vehicles and wind turbines.

Recycling these magnets could provide a new source of rare earth oxides, reducing reliance on traditional mining operations and global supply chains, particularly from China.

The company is looking to process magnetic rare earth concentrates from sources outside the Asian nation, potentially boosting the production of rare earth elements like dysprosium and terbium.

These elements are critical for various industries, including energy, electronics and defense.

NioCorp plans to begin testing the feasibility of recycling NdFeB magnets once it secures sufficient funding. It aims to research processes to de-magnetize, prepare and grind used magnets into feedstock that could be converted back into separated rare earths products at the Elk Creek facility through NioCorp’s planned chemical processes.

If successful, this could allow NioCorp to increase its planned production of neodymium-praseodymium oxide, dysprosium oxide and terbium oxide beyond what is contained in the Elk Creek ore.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Wheaton Precious Metals ( TSX:WPM,NYSE:WPM)announced the launch of the Future of Mining Challenge, a global competition aimed at advancing technological innovation in the mining sector.

The initiative, developed in collaboration with Foresight Canada, seeks to foster solutions that will reduce greenhouse gas emissions and improve overall efficiency in mining operations.

The focus is on technology that can reduce the environmental impact of base and precious metals mining, in line with Wheaton’s commitment to addressing challenges revolving around carbon emissions and efficiency.

Cleantech companies and innovators from around the world are invited to participate. The goal is to identify scalable solutions that can be applied to mining operations across the globe.

A US$1 million prize will be awarded to the winner, with applications opening on Wednesday (September 18).

Randy Smallwood, president and CEO of Wheaton Precious Metals, emphasized the critical role that mining plays in the global economy. “It is critical that we foster innovation and collaboration to improve the future of mining, with a goal of making current practices more efficient and sustainable,” he said in a press release.

Foresight Canada specializes in fostering clean technology innovation, and CEO Jeanette Jackson echoed the dual objective of the competition: reducing emissions while enhancing productivity and profitability in the mining sector.

‘By working together, we will seek to identify solutions whose goal is to not only reduce emissions but enhance the productivity and profitability of the global mining sector. We are excited to see the innovations that emerge,’ she noted.

A panel of industry experts will review the proposals, and the winner will be announced at next year’s Prospectors & Developers Association of Canada convention, scheduled to run from March 2 to 5, 2025, in Toronto, Canada.

The deadline for Future of Mining Challenge applications will be at the end of the year.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Resource investors new to the market might see quite a few unfamiliar phrases in news releases. Prefeasibility and feasibility studies are definitely two key mining terms to know.

Prefeasibility and feasibility studies are inherently linked to each other — understanding their differences creates a clearer idea of what they are and how they’re used. Their key similarity is that they represent milestones for mining and exploration companies.

On that note, let’s take a closer look at what exactly prefeasibility and feasibility studies are, as well as how they fit into company plans and the lifecycle of a mining project.

What is a prefeasibility study?

A prefeasibility study (PFS) is an early stage analysis of a potential mining project. These studies are conducted by a small team and are designed to give company stakeholders the basic information they need to greenlight a project or choose between potential investments. They typically give an overview of a mining project’s logistics, capital requirements, key challenges and other information deemed important to the decision-making process, such as whether the operation will be open pit or underground.

What comes before a prefeasibility study?

Prefeasibility studies are usually preceded by sufficient mineral exploration work, including drilling, to inform a mineral resource report, a potential model of the orebody and a scoping study.

What is a scoping study?

A scoping study, also known as a preliminary economic assessment or a PEA, is a study that includes initial technical and economic analysis of the potential viability of a project’s mineral resources.

PEAs should include base-case data on the capital costs associated with bringing a project into production, an estimate of how the mine will operate once it is built, how much metal and money it will produce and what operating costs it will incur. PEAs help mining companies understand risks and uncertainties associated with a project by providing information on pre-production capital costs, life-of-mine sustaining capital, mine life and cash flow, as well as details on processing and production methods and rates.

When and why do companies undertake prefeasibility studies?

Following a preliminary mineral resource report and the creation of an orebody model, a PFS acts as one of the first explorations of a potential investment. Companies use these studies to collect information before investing millions of dollars into tasks like acquiring permits or research equipment.

What information does a prefeasibility study include?

In addition to information relating to geological models and mine design, prefeasibility studies take into account factors that may impact or interfere with the final project. That can involve community issues, geographic obstacles, permit challenges and more.

A comprehensive PFS should include detailed designs and descriptions for the mining operation, as well as cost estimates, project risks, safety issues and other important information. There should also be multiple options included in the study for tackling different issues, as that will provide organizations with more ways to overcome potential challenges.

What happens if prefeasibility study results are positive? Negative?

If a PFS shows a positive base-case scenario, the company will likely move on to the next stage, a feasibility study. If the study is negative, an organization may head back to the drawing board or abandon the potential project altogether.

What is a feasibility study?

A feasibility study is an in-depth evaluation of a mining project with and established mineral resource. These studies are intended to evaluate if a mineral reserve can be mined effectively and if it will be profitable. Detailed mining feasibility studies are also used as the basis for a project’s capital estimates, operating costs and overall economic viability.

What is the difference between prefeasibility and feasibility studies?

While the cover many of the same topics, the main difference between prefeasibility and feasibility studies is that the latter are meant to be much more accurate and require more resources to complete. Feasibility studies should offer estimates that are within 10 to 20 percent accuracy, whereas prefeasibility studies are allowed to run between 20 and 30 percent.

When and why do companies undertake feasibility studies?

At this point in the process, organizations already have large sums of money at stake and a drive to see their project through to completion. Feasibility studies are all about reducing risks and addressing potential issues that may complicate a mining project. The studies also include information that is helpful for stakeholders such as local governments or environmental analysts.

In a guide to feasibility studies, Don Hofstrand and Mary Holz-Clause of Iowa State University note, “A feasibility study is usually conducted after producers have discussed a series of business ideas or scenarios.” The number of business alternatives being considered can be reduced from here.

What information do feasibility studies include?

Feasibility studies cover many important points, including economic, legal, operational and scheduling issues. Feasibility studies should be able to address questions across these topics and feature information about the technical feasibility of a project, as well as how much it will cost, whether it’s in accordance with the law, how operations will work and when it can be completed.

Market analysis research can also be a vital part of the feasibility study phase. This type of research is intended to ensure that there is demand for the metal or commodity a project may produce. Market research also helps to zero in on competition in the marketplace. This type of information on markets and demand is especially valuable for investors.

What happens if the feasibility study results are positive? Negative?

Feasibility studies act as tools that provide CEOs and mining engineers with as much detailed information as possible to make intelligent and strategic decisions regarding the development of a project. Positive results will likely move the project forward as is. Decisions will vary, but reactions to negative results can include choices like canceling projects, bringing in partners, increasing investment or changing schedules.

Why should investors care?

Both prefeasibility and feasibility studies can provide investors with useful updates on the progress of a company’s project. These studies help create a more concrete picture about a company’s milestones and challenges moving forward.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

CleanTech Lithium PLC (AIM:CTL, Frankfurt:T2N, OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, announces it has completed due diligence on the use of industrial forward osmosis (iFO) as an alternative to using a standard thermal evaporator for eluate concentration in it´s pilot plant conversion stage. iFO provides several benefits to optimise the downstream process to produce battery-grade lithium carbonate.

Highlights:

CTL has investigated utilising iFO for eluate concentration, the first step in the downstream conversion process, with the method achieving higher water recovery and up to 60% lower energy consumption and CO2 emissions compared to using conventional thermal evaporatorsiFO also has high efficiency when utilising solar thermal for power supply An iFO demonstration unit, provided by Forward Water Technology based in Canada, is preparing for shipment from Toronto to the facilities of Conductive Energy in Chicago, USAConductive Energy will convert the eluate produced from our DLE pilot plant in Copiapó, Chile, using feed brine from Laguna Verde, into battery grade lithium carbonateAn initial volume of 88m3 of concentrated eluate, equal to approximately one tonne of lithium carbonate equivalent (LCE), is at Conductive Energy´s facility, with transport and commissioning of the iFO unit expected to take approximately two weeks

Steve Kesler, Executive Chairman and Interim CEO, of CleanTech Lithium PLC, said:

‘Our team has undertaken a tremendous amount of work on selecting and optimising the DLE process for the Laguna Verde project, and this has extended to the downstream conversion process where we are working with Conductive Energy. Previous test-work confirmed that a downstream process has been developed that will efficiently produce battery-grade lithium carbonate for the Laguna Verde project at pilot scale, including use of Forward Osmosis which we are investigating as an alternative for eluate concentration. This has the potential to lower energy consumption, CO2 emissions and both capital and operating costs.’

Further Information

CleanTech Lithium has engaged Conductive Energy for the conversion of lithium chloride eluate, produced using feed brine from Laguna Verde at our DLE pilot plant in Copiapó, Chile, into battery-grade lithium carbonate. Four containers of eluate with a total volume of 88m3 have been received by Conductive Energy at its Chicago, USA, facility with conversion to begin in October 2024. Conductive Energy´s conversion process is shown in Figure 1 which is based on standard industry process steps, other than the trialing of Forward Osmosis in the eluate concentration stage as an alternative to using a relatively more energy intensive thermal evaporator.

Figure 1: Conductive Energy Conversion Process

As due diligence in investigating alternative technologies capable of improving process performance, iFO was trialed in process test-work on a 200L sample of eluate undertaken at Conductive Energy´s facilities in Q2 2024. The full results of this test-work, which produced a sample of battery grade lithium with a purity of 99.75% lithium carbonate, was reported to the market on July 22, 2024. Results of the iFO stage of the test work achieved very good performance supporting the replacement of a thermal evaporator in concentrating eluate, with the key parameters and results provided in Table 1:

Parameter

Unit

Concentrated Eluate

R/O Concentrate

iFO Concentrate

Lithium (Li)

mg/L

2,194

5,700

18,000

Total Dissolve Solids (TDS)

mg/L

19,260

62,000

190,000

Laboratory

ALS Chile

Lambton.Scientific

Lambton.Scientific

Volume

L

215.5

66.3

13.9

Reduction in Volume

%

69.3%

94%

Table 1: Results from concentration of Laguna Verde eluate through R/O followed by iFO

A concentration of 18,000mg/L Li was set as the target concentration during iFO testing, representative of a typical lithium concentration used in the carbonation conversion process. Based on the Laguna Verde eluate, iFO can concentrate lithium up to 50,000 mg/L Li. Total water recovery of 94% was achieved during the eluate concentration, with the remaining 6% recycled or returned in the process. The DLE adsorbent used to produce the concentrated eluate achieved very high impurity rejection rates, except for boron, as previously reported (RNS July 22, 2024).

iFO testing was optimised for boron removal resulting in a 55% reduction based on weight. The achieved boron reduction is significant enabling improved process efficiency and product quality, while reducing energy consumption and operating costs associated with removal of boron using Ion Exchange (IX), which is the last process step prior to carbonation. In the Laguna Verde PFS currently underway, recovering this boron as a saleable by-product is being investigated.

Other benefits of iFO use include a 60% reduction in energy consumption compared to conventional thermal evaporators, and up to 80% if operated using a renewable energy source such as solar thermal as depicted in Figure 2 below. iFO´s low energy use when compared to thermal evaporation enables CO2 emission reduction by up to 60%, underscoring the sustainability benefits of this innovative technology.

Figure 2: Depiction of commercial scale iFO plant with solar thermal power supply

As a result of iFO performance during testing, CTL requested Conductive Energy to replace the thermal evaporator with iFO during the downstream conversion process for the next stage of conversion test-work, in which additional iFO operating information can be obtained such as energy requirements. A iFO demonstration unit with the capacity to process 35 m3/day of concentrated eluate will be supplied by Forward Water Technologies, which is shown in Figure 3 below, when final commissioning was underway. The unit is now ready for shipment from Toronto, Canada, and is expected to arrive at the Conductive Energy facility in Chicago, USA, in approximately one week. A further one week of on site commissioning is planned before the eluate conversion process will commence.

Figure 3: iFO demonstration unit with capacity to process 35 m3/day of eluate in final commissioning

Competent Persons

The following professional acts as qualified person, as defined in the AIM Note for Mining, Oil and Gas Companies (June 2009) and JORC Code (2012):

Marcelo Bravo: Chemical Engineer (Universidad Católica del Norte), has a Master’s Degree in Engineering Sciences major in Mineral Processing, Universidad de Antofagasta. He currently works as a Senior Process Consulting Engineer at the Ad-Infinitum company. Mr Bravo has relevant experience in researching and developing potassium, lithium carbonate, and solar evapo-concentration design processes in Chile, Argentina, and Bolivia. Mr Bravo, who has reviewed and approved the information contained in the chapters relevant to his expertise contained in this announcement, is registered with No. 412 in the public registry of Competent Persons in Mining Resources and Reserves per the Law of Persons Competent and its Regulations in force in Chile. Mr Bravo has sufficient experience relevant to the metallurgical tests and the type of subsequent processing of the extracted brines under consideration and to the activity being carried out to qualify as a competent person, as defined in the JORC Code. Mr Bravo consents to the inclusion in the press release of the matters based on his information in the form and context in which it appears.

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon publication of this announcement, this inside information is now considered to be in the public domain. The person who arranged for the release of this announcement on behalf of the Company was Gordon Stein, Director and CFO.

For further information contact:

CleanTech Lithium PLC

Steve Kesler/Gordon Stein/Nick Baxter

Jersey office: +44 (0) 1534 668 321

Chile office: +562-32239222

Or via Celicourt

Celicourt Communications

Felicity Winkles/Philip Dennis/Ali AlQahtani

+44 (0) 20 7770 6424

cleantech@celicourt.uk

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish/Asia Szusciak

+44 (0) 20 7628 3396

Fox-Davies Capital Limited (Joint Broker)

Daniel Fox-Davies

+44 (0) 20 3884 8450

daniel@fox-davies.com

Canaccord Genuity (Joint Broker)

James Asensio

+44 (0) 20 7523 4680

Beaumont Cornish Limited (‘Beaumont Cornish’) is the Company’s Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish’s responsibilities as the Company’s Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes

CleanTech Lithium (AIM:CTL, Frankfurt:T2N, OTCQX:CTLHF) is an exploration and development company advancing sustainable lithium projects in Chile for the clean energy transition. Committed to net-zero, CleanTech Lithium’s mission is to produce material quantities of sustainable battery grade lithium products using Direct Lithium Extraction technology powered by renewable energy. The Company plans to be a leading supplier of ‘green’ lithium to the EV and battery manufacturing market.

CleanTech Lithium has two key lithium projects in Chile, Laguna Verde and Viento Andino, and hold licences in Llamara and Salar de Atacama, located in the lithium triangle, a leading centre for battery grade lithium production. The two major projects: Laguna Verde and Viento Andino are situated within basins controlled by the Company, which affords significant potential development and operational advantages. All four projects have direct access to existing infrastructure and renewable power.

CleanTech Lithium is committed to using renewable power for processing and reducing the environmental impact of its lithium production by utilising Direct Lithium Extraction with reinjection of spent brine. Direct Lithium Extraction is a transformative technology which removes lithium from brine, with higher recoveries than conventional extraction processes. The method offers short development lead times with no extensive site construction or evaporation pond development so there is minimal water depletion from the aquifer. www.ctlithium.com

Source

Click here to connect with CleanTech Lithium PLC (AIM:CTL, OTCQX:CTLHF, Frankfurt:T2N), to receive an Investor Presentation

This post appeared first on investingnews.com

Israel has added another objective to its ongoing conflict with Hamas and Hezbollah: ensuring the safe return of residents from communities along its border with Lebanon to their homes.

The country’s security cabinet voted on the measure during a late night meeting that lasted into the early hours of Tuesday, Prime Minister Benjamin Netanyahu’s office said, adding that “Israel will continue to act to implement this objective.”

Though the return of residents of northern Israel has long been understood to be a political necessity, this is the first time it has been made an official war goal.

Officials and residents from Israel’s northern region have become increasingly vocal about the need to return to their homes, piling pressure on the government to act against the threat of Hezbollah’s rockets from southern Lebanon.

The addition of the new war aim may push Israel to shift its military focus to its northern front as it warns that its patience for reaching a diplomatic solution with Hezbollah is running thin.

Earlier on Monday, Netanyahu told US envoy Amos Hochstein in Tel Aviv that it won’t be possible to return the northern residents without a “fundamental change in the security situation in the north,” according to his office. He added that Israel will “do what is necessary” to safeguard the region’s security and return the residents to their homes.

Defense Minister Yoav Gallant was however more specific, saying in a post on X after meeting Hochstein that the only way to allow the residents of the north to return is “though military action.”

Hochstein cautioned Netanyahu against initiating a wider war in Lebanon, Axios reported, citing sources it didn’t identify.

Hezbollah has said that it will end its attacks on Israel when Israel ends its war in Gaza.

Gallant’s fate

The addition to Israel’s war aims comes amid reports in Israel that Netanyahu plans to replace Gallant with a former rival politician, Gideon Sa’ar. Unlike Gallant, who served for decades in the Israel Defense Forces, Sa’ar is a near lifelong politician. Reports of his potential appointment as defense minister have already caused a stir in Israel’s political and military establishment.

Netanyahu’s attempt to fire Gallant in March last year due to Gallant’s opposition to the government’s plan to overhaul the judiciary prompted large public protests. The prime minister eventually backed down. On Monday evening, crowds gathered outside Sa’ar’s house in Tel Aviv to protest his potential appointment and express concerns about its possible impact on the fate of the hostages in Gaza.

Opposition leader Benny Gantz on Tuesday slammed reports of Gallant’s potential dismissal.

“Replacing a minister of defense on the brink of a possible more intense campaign in the north, which could turn into a regional war is, in my opinion, is irresponsible security-wise,” he said in a statement. He said the addition of the new war aim was “better late than never.”

This post appeared first on cnn.com